January 13th, 2022 | 18:11 CET
New research results for Covid-19: BioNTech, Cardiol, Valneva
In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , VALNEVA SE EO -_15 | FR0004056851
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
How long will vaccine shares benefit from the hype?
The share of the Mainz-based biotech company BioNTech leads the top of the most executed orders again today. On Tradegate, the share can show 3,137 orders so far. At a price of EUR 184.05, the share is trading 4.46% down. Valneva's stock last traded at EUR 16.61, down 2.92%.
Cannabis can prevent viral infection
Oregon State University researchers this week presented their research report titled "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants." According to the report, researchers found that two cannabinoid acids, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), found in cannabis, can bind to the spike protein of SARS-CoV-2, the virus that causes covid-19.
Biotech company Cardiol Therapeutics is also relying on cannabidiol in its development of therapeutic options for heart problems. The company received a USD 50 million cash injection in November 2021, allowing it to move forward with clinical trials. Treatment of myocarditis may also be among the company's future therapies. In light of the fact that myocarditis is also one of the side effects of current vaccination campaigns around the globe, a successful completion of the clinical trial would be in the public interest. It is possible that investors will soon switch from vaccine shares. Cardiol's share was last quoted at EUR 1.58 and can gain 2.60%. The analysts at GBC Research recommend the share as a buy with a price target of CAD 17.49.
More information is expected from the company at the International Investment Forum (IIF), on Feb. 17, 2022. (Free to attend: ii-forum.com).
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
